Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Rare Diseases

Melanoma

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Neuroendocrine Tumor

Neuroepithelioma

All Drugs and Chemicals

Antineoplastic Agents

Antirheumatic Agents

Anti-Infective Agents

Vaccines

Cyclophosphamide

Poly ICLC

Monatide (IMS 3015)

Freund's Adjuvant

Immunologic Factors

Immunosuppressive Agents

Antineoplastic Agents, Alkylating

Alkylating Agents

Adjuvants, Immunologic

Interferons

Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.

Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:

* Day -6 (Cycle 1)
* Day 8 (Cycle 2)
* Day 22 (Cycle 3)
* Day 36 (Cycle 4)
* Day 50 (Cycle 5)

Part 1: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.

Parts 1 and 2: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:

* Day -6 (Cycle 1)
* Day 8 (Cycle 2)
* Day 22 (Cycle 3)
* Day 36 (Cycle 4)
* Day 50 (Cycle 5)

6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

6MHP

Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant

Montanide ISA-51

polyICLC

Craig L. Slingluff, Jr., MD

This study evaluates whether it is safe to administer a peptide vaccine in combination with different adjuvants. Adjuvants are substances that may boost immune responses vaccines. In this study, the adjuvants are Montanide ISA-51, polyICLC and cyclophosphamide. This study will also evaluate the effects of the combination of the peptide vaccine and the adjuvants on the immune system. The investigators will monitor these effects by performing tests in the laboratory on participants' blood, a lymph node, and tissue from the sites of vaccination.

Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma

A Trial to Evaluate the Immunogenicity and Safety of a Melanoma Helper Peptide Vaccine Plus Novel Adjuvant Combinations (MEL63)

Treatment-related adverse events, by CTCAE v4, Dose-limiting toxicities.

CD4+ T cell responses to 6 MHP: durable helper T cell response to 6MHP at 2 or more consecutive timepoints in the PBMC.

increased infiltration of CD4+ and CD8+ T lymphocytes into melanoma metastases

CD8+ T cell responses to defined melanoma antigens

Ludwig Institute for Cancer Research

Cancer Research Institute, New York City

Craig L Slingluff, Jr

Director, Human Immune Therapy Center

The study will be monitored continuously for treatment-related adverse events.

A DLT is defined as any unexpected adverse event that is possibly, probably or definitely related to treatment and meets the following criteria:

* ≥ Grade 3
* ≥ Grade 1 ocular adverse events as defined below
* ≥ Grade 2 allergic/autoimmune reactions as defined below Exceptions are made for small vaccine site ulceration, and for some transient systemic AEs.

Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.

6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant

Arm A:6MHP + Montanide ISA-51

Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:

* Day -6 (Cycle 1)
* Day 8 (Cycle 2)
* Day 22 (Cycle 3)
* Day 36 (Cycle 4)
* Day 50 (Cycle 5)

  6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant

Cyclophosphamide: Cyclophosphamide, systemic adjuvant

Arm B:6MHP + Montanide ISA-51 + Cyclophosphamide

Part 1: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.

6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant

polyICLC: polyICLC, local adjuvant

Arm C:6MHP + polyICLC + Montanide ISA-51

Parts 1 and 2: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:

* Day -6 (Cycle 1)
* Day 8 (Cycle 2)
* Day 22 (Cycle 3)
* Day 36 (Cycle 4)
* Day 50 (Cycle 5)

  6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant

polyICLC: polyICLC, local adjuvant

Cyclophosphamide: Cyclophosphamide, systemic adjuvant

Arm D:6MHP + polyICLC + Montanide ISA-51 + Cyclophosphamide

Total

Age, Continuous

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

United States

Region of Enrollment

Each participant was staged according to AJCC version 7 criteria at the time of study enrollment. Risk of death is generally higher for stage III than stage II, and within each stage, risk is higher for stage C than B than A. For those enrolled within 6 months of definitive therapy of the original diagnosis, the stage at diagnoses is used. For those enrolled after a subsequent recurrence or metastasis, the stage at recurrence was used.

AJCC stage (v7)

Craig Slingluff, MD, Professor of Surgery

All 48 participants , including 47 on part 1 and 1 on part 2.

Number of Participants With Adverse Events

All ennrolled and treated patients on Parts 1 and 2 of the study.

Immunogenicity-CD4+ T Cell Responses

CD8 T cells per mm2 in tumor pre-vaccine (day 0)

CD8 T cells per mm2 in tumor day 22

CD4 T cells per mm2 of tumor prevaccine (day 0)

CD4 T cells per mm2 tumor day 22

One patient enrolled on Part 2, was on Arm D.

Immunogenicity-modification of the Tumor Microenvironment (Part 2 Only)

Data were not collected for this endpoint. Funding for this trial has ended.

Immunogenicity-CD8+ T Cell Responses

Overall Study

Pharmaceutical Solutions

Ipilimumab

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

The vaccine drug product, 6MHP, consists of 6 class II MHC-restricted peptides derived from melanoma proteins. Each vaccine consists of 200 mcg of each of the six peptides. An aqueous solution of vaccine is mixed 1/1 with Montanide ISA-51 to form water-in-oil emulsions. Vaccines are administered days 1, 8, 15, 43, 64, and 85. All peptide vaccines are administered intradermally and subcutaneously.

Ipilimumab will be administered in accord with the official prescribing information: 3 mg/kg intravenously once every 3 weeks, for 4 doses. Ipilimumab will be administered on days 1, 22, 43, and 64.

Elizabeth Gaughan, MD

This study evaluates whether it is safe to administer a peptide vaccine with ipilimumab. This study will also evaluate the effects of the combination of the peptide vaccine and ipilimumab on the immune system. The investigators will monitor these effects by performing tests in the laboratory on participants' blood, a lymph node, and tumor samples.

A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma

A Phase I/II Trial to Evaluate the Safety and Immunogenicity of a Helper Peptide Vaccine Plus CTLA-4 Blockade in Melanoma Patients (Mel62; 6PAC)

Adverse event profile for the combination of ipilimumab and 6MHP

CD4+ T cell responses to the peptide vaccine, defined as:

1. any CD4+ T cell response to 6 melanoma helper peptides (6MHP) in peripheral blood mononuclear cells (PBMC) with a 10 fold (or greater) increase in response over background (high response) by ex vivo ELIspot assay.
2. CD4+ T cell high responses to 6MHP in PBMC at at least 2 consecutive time points having peripheral blood mononuclear cells (PBMC) with a 10 fold (or greater) increase in response over background by ex vivo ELIspot assay.
3. CD4+ T cell high response to 6MHP in sentinel immunized lymph node (SIN).

An evaluation of epitope-spreading for CD8+ T cells in the blood and the sentinel immunized node that are reactive to a panel of defined melanoma antigens.

The vaccine drug product, 6MHP, consists of 6 class II MHC-restricted peptides derived from melanoma proteins. Each vaccine consists of 200 mcg of each of the six peptides. An aqueous solution of vaccine is mixed 1/1 with Montanide ISA-51 to form water-in-oil emulsions. Vaccines are administered days 1, 8, 15, 43, 64, and 85. All peptide vaccines are administered intradermally and subcutaneously.

Ipilimumab will be administered in accord with the official prescribing information: 3 mg/kg intravenously once every 3 weeks, for 4 doses. Ipilimumab will be administered on days 1, 22, 43, and 64.

Ipilimumab: Checkpoint blockade inhibitor

6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

6MHP and Ipilimumab

Age, Categorical

Craig L. Slingluff, Jr. MD

Number of participants with DLTs

Participants with any treatment-related AEs

All eligible enrolled and treated patients. Partiipants analyzed for any adverse event (AE) and for dose limiting toxicities (DLT).

Safety (Adverse Event Profile)

CD4+ T Cell Responses in the Blood and in the Sentinel Immunized Node

Epitope Spreading (Epitope-spreading for CD8+ T Cells in the Blood and the Sentinel Immunized Node)

Trametinib

Dabrafenib

Vemurafenib

The vaccine drug product, 6MHP, consists of 6 class II MHC-restricted peptides derived from melanoma proteins. Each vaccine consists of 200 mcg of each of the six peptides. An aqueous solution of vaccine is mixed 1/1 with Montanide ISA-51 to form water-in-oil emulsions. Vaccines are administered days 1, 8, 15, 36, 57, 78. All peptide vaccines are administered intradermally and subcutaneously.

A selective BRAF inhibitor and a selective MEK inhibitor will be administered in accordance with the prescribing information.

BRAF inhibitor

MEK inhibitor

This study evaluates whether it is safe to administer a helper peptide vaccine with BRAF inhibitor and MEK inhibitor therapy. This study will also evaluate the effects of the combination of the peptide vaccine and BRAF inhibitors/MEK inhibitors on the immune system. We will monitor these effects by performing tests in the laboratory on participants' blood and tumor samples.

A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib

A TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A HELPER PEPTIDE VACCINE PLUS COMBINATION OF BRAF INHIBITION AND MEK INHIBITION (MEL61)

CD4+ T cell responses to the peptide vaccine

An evaluation of the development of antibdoy responses following vaccination

National Cancer Institute (NCI)

Professor of Surgery and Director, Human Immune Therapy Center

Antibodies

Antibodies, Monoclonal

Immunoglobulins

200 mcg of 6MHP plus 0.9 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered subcutaneously on days 1, 8, 15, and 36. 200 mcg of 6MHP in Montanide ISA-51 adjuvant (without polyICLC) will be administered subcutaneously/intradermally on day 176. CDX-1127 (3mg/kg) will be administered intravenously on days 1, 36, and 78.

200 mcg of 6MHP plus 0.9 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered subcutaneously on days 1, 8, 15, and 36. 200 mcg of 6MHP in Montanide ISA-51 adjuvant (without polyICLC) will be administered subcutaneously/intradermally on day 176.

CDX-1127

Craig L Slingluff, Jr., MD

This study evaluates whether it is safe to administer a peptide vaccine (6MHP) with adjuvants and the CDX-1127 monoclonal antibody, and whether the adjuvants and the CDX-1127 monoclonal antibody boost immune responses to the vaccine. In this study, the adjuvants are Montanide ISA-51 and polyICLC. The investigators will monitor these effects by performing tests in the laboratory on participants' blood and tissue from a vaccine site.

Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

Evaluation of Safety and Durable Immunogenicity of Melanoma Vaccination, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

All IPD that underlie results in a publication will be shared starting 1 year after publication.

Number of participants with dose-limiting toxicities based on CTCAE v5.0

Number of participants with CD4+ T cell responses to 6 MHP persisting to day 127 or later.

Number of regulatory T cells per mm2 in the vaccine site microenvironment

Percent of circulating regulatory T cells among CD4+ T cells

Number of participants with circulating CD4+ Th1 responses to vaccine antigens

Number of participants with durable CD4+ Th1 memory response to vaccine antigens, measured as response at two or more consecutive time points

Number of participants with CD4+ Th1 memory response to vaccine antigens a week after the Day 176 booster vaccine.

Celldex Therapeutics

Professor of Surgery; Director, Human Immune Therapy Center

Ocular Melanoma

Intraocular Melanoma

Amino Acids

Histidine

6MHP (200mcg of each peptide) and 300mcg of NeoAg-mBRAF will be co-administered locally with 0.9mg of polyICLC and CDX-1140. There will be a dose escalation of CDX-1140 (50mcg, 200mcg, 800mcg, 3.0mg). A vaccine containing all of these components will be given on days 1, 22, 43, and 64. The vaccine will be given subcutaneously/intradermally.

BRAF 586-614 (V600E) peptide to which a histidine has been added to the N-terminus, resulting in BRAF 585-614 (V600E).

NeoAg-mBRAF

PolyICLC

CDX-1140

This study evaluates whether it is safe to administer a peptide vaccine made of 6MHP and a mutated neoantigen peptide (BRAF585-614-V600E) combined with adjuvants. The adjuvants that will be used in this trial are a CD40 antibody (CDX-1140) and a toll-like receptor (TLR) 3 agonist (Poly-ICLC). The study will also investigate the effects of the vaccine and the adjuvants on the immune response. The investigators will monitor these effects by performing tests in the laboratory on participants' blood and skin tissue.

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

Enhanced Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists in Patients With Melanoma

Number of participants with durable or persistent CD4+ Th1 responses to the melanoma vaccine at either day 85 or day 176, or both

Number of FoxP3+ CD4+ T cells per mm\^2 in vaccine site biopsies

Number of participants with circulating Tregs (CD4+ FoxP3+) as a proportion of circulating CD4 T cells

Number of participants with CD4+ T cell response; maximum increase after vaccination at any time point.

Number of participants with CD4+ T cell response to the melanoma peptides

Pembrolizumab

6MHP (200 mcg each peptide) will be administered intradermally and subcutaneously on days 1, 8, 15, 43, 64, and 85. Pembrolizumab (200 mg) will be administered intravenously every 3 weeks for up to 2 years, beginning on day 1.

Humanized monoclonal antibody (mAb) specific for PD-1.

This study evaluates whether it is safe to administer a peptide vaccine in combination with pembrolizumab. This study will also evaluate the effects of the combination of the peptide vaccine and pembrolizumab on the immune system. The investigators will monitor these effects by performing tests in the laboratory on participants' blood, a lymph node, and tumor samples.

Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab

A Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus PD-1 Blockade

Number of participants with dose-limiting toxicities on treatment with combination of pembrolizumab and 6MHP.

Circulating CD4+ T cell responses to 6MHP peptides were assessed using IFN-γ ELISpot assays directly ex vivo for peripheral blood mononuclear cells (PBMC) and sentinel immunized node (SIN) lymphocytes. For each sample, the following definitions applied: Nvax=number of T cells responding to vaccine peptide; Nneg=number of T cells responding to maximum negative control; Rvax=Nvax/Nneg. For PBMC, a participant was considered to have a T-cell response (Rsp) if all the following were true: (1) Nvax exceeded Nneg by ≥ 20/100,000 CD4+ cells (0.02%), (2) (Nvax-1 SD)≥(Nneg+1 SD), (3) Rvax ≥2×, and (4) Rvax postvaccine ≥2x Rvax prevaccine. Criteria for CD4+ Rsp in a SIN included criterion (1-3). A high durable T cell response (hdRsp) required a 5× increase above baseline in any two or more time points (through day 85), and a durable immune response (dRsp) required only a 2× increase over background. A response in either PBMC or in SIN is considered a response for this endpoint.

Evaluation of tumor infiltration by T cells.Tumor biopsies were obtained pretreatment and day 22 for 12 participants and were evaluated with multiplex immunofluorescence histology (mIFH). CD8+ T cell data were evaluated. CD4+ T cells were not reported because of technical challenges with that antibody. These 12 participants with evaluable tumor samples included 3 on the PD-1 antibody-naive cohort, and 9 on the antibody-experienced cohort.

Evaluation of cytokine profile for CD4+ T cells in tumor microenvironment. Data for this outcome have not been collected due to completion of funding for this study.

Evaluation of epitope-spreading through the measurement of the induction of CD8+ T cell responses to defined melanoma antigens.

Participants who had not previously received a PD-1 or PD-L1 antibody were eligible for this cohort.

They received 6MHP vaccine (200 mcg each peptide) emulsified in Montanide ISA-51 adjuvant and administered intradermally and subcutaneously on days 1, 8, 15, 43, 64, and 85. Pembrolizumab (200 mg) was administered intravenously every 3 weeks for up to 2 years, beginning on day 1.

6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

Pembrolizumab: Humanized monoclonal antibody (mAb) specific for PD-1.

6MHP + Pembrolizumab (PD-1 Antibody-naive Cohort)

Participants who had previously received a PD-1 or PD-L1 antibody were eligible for this cohort.

They received 6MHP vaccine (200 mcg each peptide) emulsified in Montanide ISA-51 adjuvant and administered intradermally and subcutaneously on days 1, 8, 15, 43, 64, and 85. Pembrolizumab (200 mg) was administered intravenously every 3 weeks for up to 2 years, beginning on day 1.

6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

Pembrolizumab: Humanized monoclonal antibody (mAb) specific for PD-1.

6MHP + Pembrolizumab (PD-1 Antibody-experienced Cohort)

Age at enrollment

Age, Customized

Race at Enrollment

Race/Ethnicity, Customized

This measure of performance status refers to a scale from 0 to 5. Grade 0 refers to normal health with full activity and normal activity performance. Grade 1 refers to the status where individuals are restricted in strenuous activity but they are ambulatory and able to perform light or sedentary work. Eligibility for this trial required ECOG performance status of 0 to 1.

ECOG Performance Status

Craig Slingluff, MD

DLT was defined as unexpected adverse event (AE) at least possibly related to treatment, and, for 6MHP, grade ≥3 hematological or non-hematological toxicity, except that vaccine site ulcers were considered DLTs if ulcer \>2cm, required antibiotics or debridement; and for pembrolizumab, required permanent discontinuation per specified guidelines. Also considered DLTs were selected grade ≥2 ocular AEs, and AEs that led to stopping treatment even if they did not meet prespecified DLT criteria.

Number of Participants With Dose-limiting Toxicities.

CD4 T cell response (Rsp)

CD4 high durable T cell response (hdRsp)

CD4 durable T cell response (dRsp)

CD4+ T Cell Responses Detected in the Peripheral Blood or Vaccine-draining Lymph Node (Sentinel Immunized Node).

CD8 T cells per mm^2 in day 0 tumor

CD8+ T cells per mm^2 in day 22 tumor

Participants received 6MHP vaccine (200 mcg each peptide) emulsified in Montanide ISA-51 adjuvant and administered intradermally and subcutaneously on days 1, 8, 15, 43, 64, and 85. Pembrolizumab (200 mg) was administered intravenously every 3 weeks for up to 2 years, beginning on day 1.

6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

Pembrolizumab: Humanized monoclonal antibody (mAb) specific for PD-1.

6MHP + Pembrolizumab (PD-1-experienced Cohort)

Number of T Cells in the Tumor Microenvironment

Immune signature data have not been collected from the tumor microenvironment.

Level of Th1-dominant Immune Signatures in the Tumor Microenvironment

Due to completion of funding for this study, data have not been collected to assess epitope-spreading through the measurement of the induction of CD8+ T cell responses to defined melanoma antigens.

Number of CD8+ T Cell Responses to Defined Melanoma Antigens

Antibody responses to 6MHP have not been measured, due to completion of funding for this trial.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma	NCT02425306	Melanoma	6MHP Montanide ISA-5... polyICLC Cyclophosphamid...	18 Years -	University of Virginia
Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma	NCT02425306	Melanoma	6MHP Montanide ISA-5... polyICLC Cyclophosphamid...	18 Years -	University of Virginia
A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma	NCT02385669	Melanoma	Ipilimumab 6MHP	18 Years -	University of Virginia
A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib	NCT02382549	Melanoma	BRAF inhibitor 6MHP MEK inhibitor	18 Years -	University of Virginia
A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib	NCT02382549	Melanoma	BRAF inhibitor 6MHP MEK inhibitor	18 Years -	University of Virginia
Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma	NCT03617328	Melanoma	6MHP Montanide ISA-5... polyICLC CDX-1127	18 Years -	University of Virginia
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)	NCT04364230	Melanoma Ocular Melanoma Uveal Melanoma	6MHP NeoAg-mBRAF PolyICLC CDX-1140	18 Years -	University of Virginia
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)	NCT04364230	Melanoma Ocular Melanoma Uveal Melanoma	6MHP NeoAg-mBRAF PolyICLC CDX-1140	18 Years -	University of Virginia
Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab	NCT02515227	Melanoma	6MHP Pembrolizumab	18 Years -	University of Virginia

Spots Global Cancer Trial Database for 6mhp

Every month we try and update this database with for 6mhp cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for 6mhp

Every month we try and update this database with for 6mhp cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for 6mhp cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.